Literature DB >> 21981983

Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections.

Silvina Masciotra1, J Steven McDougal, Jane Feldman, Patrick Sprinkle, Laura Wesolowski, S Michele Owen.   

Abstract

BACKGROUND: The current algorithm for HIV diagnosis in the US involves screening with an immunoassay (IA) and supplemental testing with Western blot (WB) or immunofluorescence assay. Because of existence of more sensitive and specific FDA-approved assays that would also reduce the cost and turn-around time of testing compared to WB, several alternative algorithms have been evaluated. Recently, an alternative algorithm using a sensitive 3rd or 4th generation IA followed by an HIV-1 and HIV-2 discriminatory supplemental test on the initial IA-positive specimens was proposed. Concordant positive results indicate HIV-positive specimens and discordant results are resolved by nucleic acid amplification testing (NAAT).
OBJECTIVES: To evaluate the sensitivity of assays during acute HIV infection and the performance of the current and an alternative algorithm using samples from HIV-1 seroconversion panels and persons with established HIV infections. STUDY
DESIGN: To evaluate the algorithms in early infections, 26 HIV-1 seroconverters from the US were tested with three 3rd generation and one 4th generation IA, six rapid tests (RTs), one NAAT, and WB. Sensitivity and specificity of the algorithms were calculated by testing an additional 416 HIV-positive and 414 uninfected control samples with one 3rd generation and one 4th generation IA, four RTs, one NAAT, and WB.
RESULTS: The individual assays evaluated became positive 5 (RT) to 26 days (NAAT) before WB was positive. Among seroconverters, the alternative algorithm detected significantly more infections than the current algorithm (103-134 versus 56, p<0.0001). Furthermore, the use of a 4th generation IA instead of a 3rd generation assay as the screen resulted in significantly higher detection of acute infections (p<0.0001). In contrast, the algorithms performed equally among specimens from established HIV-1 infections.
CONCLUSIONS: This study demonstrated improved sensitivity of the alternative algorithm for detecting acute HIV-1 infections, while maintaining the ability to accurately detect established HIV-1 infections. Early detection is important as individuals can be highly infectious during acute infection. In addition, the alternative algorithm should reduce turn-around time by using a RT as the supplemental test has the potential to increase the number of test results returned. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21981983     DOI: 10.1016/j.jcv.2011.09.011

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  45 in total

1.  HIV nucleic acid amplification testing versus rapid testing: it is worth the wait. Testing preferences of men who have sex with men.

Authors:  Joshua D O'Neal; Matthew R Golden; Bernard M Branson; Joanne D Stekler
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

2.  Performance of an alternative HIV diagnostic algorithm using the ARCHITECT HIV Ag/Ab Combo assay and potential utility of sample-to-cutoff ratio to discriminate primary from established infection.

Authors:  Eric M Ramos; Socorro Harb; Joan Dragavon; Paul Swenson; Joanne D Stekler; Robert W Coombs
Journal:  J Clin Virol       Date:  2013-08-26       Impact factor: 3.168

3.  Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV Isolates.

Authors:  Mars Stone; John Bainbridge; Ana M Sanchez; Sheila M Keating; Andrea Pappas; Wes Rountree; Chris Todd; Sonia Bakkour; Mark Manak; Sheila A Peel; Robert W Coombs; Eric M Ramos; M Kathleen Shriver; Paul Contestable; Sangeetha Vijaysri Nair; David H Wilson; Martin Stengelin; Gary Murphy; Indira Hewlett; Thomas N Denny; Michael P Busch
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

5.  HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Authors:  Bernard M Branson
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

6.  Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression.

Authors:  Rachel Lena Rutishauser; Wendy Hartogensis; Christian Deo Deguit; Melissa Krone; Rebecca Hoh; Frederick M Hecht; Christopher D Pilcher; Peter Bacchetti; Steven G Deeks; Peter W Hunt; Joseph M McCune
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-25       Impact factor: 2.205

7.  Self-testing for HIV and its impact on public health.

Authors:  Christopher B Hurt; Kimberly A Powers
Journal:  Sex Transm Dis       Date:  2014-01       Impact factor: 2.830

8.  No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.

Authors:  Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-13       Impact factor: 2.205

9.  A multisite study of the prevalence of HIV with rapid testing in mental health settings.

Authors:  Michael B Blank; Seth S Himelhoch; Alexandra B Balaji; David S Metzger; Lisa B Dixon; Charles E Rose; Emeka Oraka; Annet Davis-Vogel; William W Thompson; James D Heffelfinger
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

10.  High HIV incidence and prevalence and associated factors among young MSM, 2008.

Authors:  Alexandra B Balaji; Kristina E Bowles; Binh C Le; Gabriela Paz-Bailey; Alexandra M Oster
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.